{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:07:39Z","timestamp":1788404859275,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Morbidity and mortality from\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      (Mtb) infection remain significant in cancer patients. We evaluated clinical characteristics, management, and outcomes in patients with active Mtb infection at our institution who had cancer or suspicion of cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively examined medical records of all patients with laboratory-confirmed active Mtb infection diagnosed between 2006 and 2014.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 52 patients with laboratory-confirmed active Mtb infection were identified during the study period, resulting in an average rate of 6 new cases per year. Thirty-two (62%) patients had underlying cancer, while 20 (38%) patients did not have cancer but were referred to the institution because of suspicion of underlying malignancy. Among patients with cancer, 18 (56%) had solid tumors; 8 (25%) had active hematologic malignancies; and 6 (19%) had undergone hematopoietic-cell transplantation (HCT). Patients with and without cancer were overall similar with the exception of median age (61\u2009years in cancer patients compared to 53\u2009years in noncancer patients). Pulmonary disease was identified in 32 (62%) patients, extrapulmonary disease in 10 (19%) patients, and disseminated disease in 10 (19%) patients. Chemotherapy was delayed in 53% of patients who were to receive such treatment. Eleven patients (all of whom had cancer) died; 3 of these deaths were attributable to Mtb infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although not common, tuberculosis remains an important infection in patients with cancer. Approximately one-third of patients were referred to our institution for suspicion of cancer but were ultimately diagnosed with active Mtb infection rather than malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-019-4586-y","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T10:03:40Z","timestamp":1573034620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Active Mycobacterium tuberculosis infection at a comprehensive cancer center, 2006\u20132014"],"prefix":"10.1186","volume":"19","author":[{"given":"Joumana","family":"Kmeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathit A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie V.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"El Chaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Prayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella J.","family":"Ariza-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Mulanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"4586_CR1","unstructured":"Organization WH. Global Tuberculosis Report 2017. World Health Organization, 2017."},{"key":"4586_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/1097-0142(197403)33:3<850::AID-CNCR2820330334>3.0.CO;2-H","volume":"33","author":"MH Kaplan","year":"1974","unstructured":"Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer. 1974;33:850\u20138.","journal-title":"Cancer."},{"key":"4586_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1469-0691.2004.00954.x","volume":"10","author":"GR De La Rosa","year":"2004","unstructured":"De La Rosa GR, Jacobson KL, Rolston KV, Raad II, Kontoyiannis DP, Safdar A. Mycobacterium tuberculosis at a comprehensive cancer Centre: active disease in patients with underlying malignancy during 1990-2000. Clin Microbiol Infect. 2004;10:749\u201352.","journal-title":"Clin Microbiol Infect"},{"key":"4586_CR4","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1002\/cncr.21541","volume":"104","author":"GM Aisenberg","year":"2005","unstructured":"Aisenberg GM, Jacobson K, Chemaly RF, Rolston KV, Raad II, Safdar A. Extrapulmonary tuberculosis active infection misdiagnosed as cancer: mycobacterium tuberculosis disease in patients at a Comprehensive Cancer Center (2001-2005). Cancer. 2005;104:2882\u20137.","journal-title":"Cancer."},{"key":"4586_CR5","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","volume":"190","author":"M Sester","year":"2014","unstructured":"Sester M, van Leth F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190:1168\u201376.","journal-title":"Am J Respir Crit Care Med"},{"key":"4586_CR6","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJMcp1005750","volume":"364","author":"CR Horsburgh Jr","year":"2011","unstructured":"Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364:1441\u20138.","journal-title":"N Engl J Med"},{"key":"4586_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/cid\/cix209","volume":"64","author":"MP Cheng","year":"2017","unstructured":"Cheng MP, Abou Chakra CN, Yansouni CP, et al. Risk of active tuberculosis in patients with Cancer: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:635\u201344.","journal-title":"Clin Infect Dis"},{"key":"4586_CR8","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1086\/503917","volume":"42","author":"M Kamboj","year":"2006","unstructured":"Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592\u20135.","journal-title":"Clin Infect Dis"},{"key":"4586_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","volume":"90","author":"PA Aristoff","year":"2010","unstructured":"Aristoff PA, Garcia GA, Kirchhoff PD, Showalter HD. Rifamycins--obstacles and opportunities. Tuberculosis (Edinb). 2010;90:94\u2013118.","journal-title":"Tuberculosis (Edinb)"},{"key":"4586_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5588\/ijtld.14.0301","volume":"19","author":"WC Fan","year":"2015","unstructured":"Fan WC, Liu CJ, Hong YC, et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. Int J Tuberc Lung Dis. 2015;19:58\u201364.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4586_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cid\/ciz048","volume":"69","author":"MP Cheng","year":"2019","unstructured":"Cheng MP, Kusztos AE, Bold TD, et al. Risk of latent tuberculosis reactivation after hematopoietic cell transplantation. Clin Infect Dis. 2019;69:869\u201372.","journal-title":"Clin Infect Dis"},{"key":"4586_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.15585\/mmwr.mm6711a2","volume":"67","author":"RJ Stewart","year":"2018","unstructured":"Stewart RJ, Tsang CA, Pratt RH, Price SF, Langer AJ. Tuberculosis - United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:317\u201323.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"4586_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1183\/09031936.06.00110205","volume":"28","author":"F Piana","year":"2006","unstructured":"Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J. 2006;28:31\u20134.","journal-title":"Eur Respir J"},{"key":"4586_CR14","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.7314\/APJCP.2013.14.12.7415","volume":"14","author":"LL Qin","year":"2013","unstructured":"Qin LL, Wang QR, Wang Q, et al. T-SPOT.TB for detection of tuberculosis infection among hematological malignancy patients and hematopoietic stem cell transplant recipients. Asian Pac J Cancer Prev. 2013;14:7415\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4586_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1378\/chest.08-2575","volume":"136","author":"L Richeldi","year":"2009","unstructured":"Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest. 2009;136:198\u2013204.","journal-title":"Chest."},{"key":"4586_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","volume":"12","author":"MX Rangaka","year":"2012","unstructured":"Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:45\u201355.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4586-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T19:10:23Z","timestamp":1604517023000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4586"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4586-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.9409\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9409\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9409\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"27 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted after obtaining approval and permissions to access the raw data, from our MD Anderson Cancer Center\u2019s Institutional Review Board, under PA15\u20130089 number, and a waiver of consent was granted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.F.C. received research grants and honoraria from Oxford Immunotec, Inc. All other authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"934"}}